Fingolimod lauryl sulfate
TASCENSO ODT is an orally disintegrating tablet prescription drug containing fingolimod lauryl sulfate, available in 0.25 mg and 0.5 mg strengths. It acts as a sphingosine 1-phosphate receptor modulator, manufactured by Cycle Pharmaceuticals Ltd for oral use. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | TASCENSO ODT is an orally disintegrating tablet prescription drug containing fingolimod lauryl sulfate, available in 0.25 mg and 0.5 mg strengths. It acts as a sphingosine 1-phosphate receptor modulator, manufactured by Cycle Pharmaceuticals Ltd for oral use. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Fingolimod lauryl sulfate",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Fingolimod lauryl sulfate — ANDA 214962 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214962"
}
]
|
| identifier | ANDA214962 |
| issued | 2016-09-16 |
| keyword |
[
"drug-manufacturers",
"drug-safety",
"fda",
"health-care",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Fingolimod lauryl sulfate |
